Latest News

Below is a selection of the latest articles and press releases covering the Resolution Therapeutics story

13/11/2023
Resolution Therapeutics’ founders present clinical proof-of-concept for macrophage cell therapy in end-stage liver disease at AASLD

Edinburgh and London, UK, 13 November 2023 - 1-year results of the MATCH Phase 2 trial of macrophage cell therapy in cirrhosis presented at AASLD

14/08/2023
Resolution Therapeutics appoints Dr. Amir Hefni as Chief Executive Officer

London, 14 August 2023 - Resolution Therapeutics announces the appointment of Dr. Amir Hefni as Chief Executive Officer

10/07/2023
Resolution Therapeutics Strengthens its Executive Team with the Appointment of Simon Ramsden as Chief Financial Officer

London, 10 July 2023 – Resolution Therapeutics announces the appointment of Simon Ramsden as Chief Financial Officer.

26/06/2023
Resolution Therapeutics Strengthens its Team with Senior Appointments

London, 26 June 2023 - Resolution Therapeutics announces the appointment of key senior hires in intellectual property, human resources and clinical operations

02/05/2023
Resolution Appoints Liver Disease Expert, Dr Clifford A. Brass, as Chief Medical Officer

London, 2 May 2023 – Resolution Therapeutics announces the appointment of Dr. Clifford A. Brass as Chief Medical Officer

30/03/2023
Resolution Expands its CMC Capabilities with Key Hires

London, 30 March 2023 - Resolution Therapeutics announces the appointment of key senior CMC hires in regulatory, quality, process development, analytical development and project management.

09/11/2022
Resolution Therapeutics Announces the Appointment of Lisa Bright as Chair of its Board of Directors

London, 9 November 2022 - Resolution announced today the appointment of Lisa Bright as Chairman of its Board of Directors

07/11/2022
Resolution Therapeutics and CCRM sign collaboration agreement to develop and scale up manufacturing for iPSC-derived macrophage cell therapies

London, UK and Toronto, Canada, 7 November, 2022 – Resolution Therapeutics and CCRM announce the signing of a collaboration in iPSC-derived macrophage cell therapies.

20/07/2022
Resolution Therapeutics Appoints Bill Symonds to its Board of Directors

London, 20 April 2021 – Resolution Therapeutics announces the appointment of Bill Symonds as a Non-Executive Director of the Company.